Vertex Ventures HC, a women-led global healthcare investment firm, has launched its third and largest fund, the $200 million Fund III, which will focus on backing life sciences and medical technology companies aiming to drive innovation and improve patient outcomes.
Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, has launched its third and largest fund, the $200 million Fund III, which will focus on backing life sciences and medical technology companies aiming to drive innovation and improve patient outcomes.
VVHC is anchored by a science-first, diversified investment strategy and is led by Managing Directors Lori Hu and Christine Brennan, who have previously led numerous investments in companies that have exited through mergers and acquisitions (M&A) or initial public offerings (IPO).
VVHC Fund III will seek investment opportunities in early-stage companies that demonstrate disruptive technologies, breakthrough research, and a clear path towards developing new medicines for patients.
Fund III will be led by Hu and Brennan and venture partner David Van Meter who joined tiger firm earlier this year and brings significant operating experience in medical technologies as the former CEO of Ivantis. In addition, industry veterans George Golumbeski, and Faheem Hasnain continue as Venture Advisors.
Since its founding in 2014, VVHC, which has $550m in assets under management, has invested in more than 25 portfolio companies to bring transformative therapies and healthcare technologies to patients, including nearly 20 clinical-stage assets and three products cleared by the US Food and Drug Administration (FDA).
